KR20220142477A - 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 - Google Patents

인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 Download PDF

Info

Publication number
KR20220142477A
KR20220142477A KR1020227031662A KR20227031662A KR20220142477A KR 20220142477 A KR20220142477 A KR 20220142477A KR 1020227031662 A KR1020227031662 A KR 1020227031662A KR 20227031662 A KR20227031662 A KR 20227031662A KR 20220142477 A KR20220142477 A KR 20220142477A
Authority
KR
South Korea
Prior art keywords
subject
amyloid
months
administration
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227031662A
Other languages
English (en)
Korean (ko)
Inventor
수잔 카탈라노
니콜라스 이조
Original Assignee
카그니션 테라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카그니션 테라퓨틱스, 인코퍼레이티드 filed Critical 카그니션 테라퓨틱스, 인코퍼레이티드
Publication of KR20220142477A publication Critical patent/KR20220142477A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227031662A 2020-02-13 2021-02-12 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 Pending KR20220142477A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976325P 2020-02-13 2020-02-13
US62/976,325 2020-02-13
PCT/US2021/018023 WO2021163613A1 (en) 2020-02-13 2021-02-12 Method of decreasing amyloid beta monomer levels in patients with cognitive decline

Publications (1)

Publication Number Publication Date
KR20220142477A true KR20220142477A (ko) 2022-10-21

Family

ID=77292728

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227031662A Pending KR20220142477A (ko) 2020-02-13 2021-02-12 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Country Status (8)

Country Link
US (1) US20230098944A1 (https=)
EP (1) EP4103604A4 (https=)
JP (2) JP2023513220A (https=)
KR (1) KR20220142477A (https=)
CN (1) CN115397849A (https=)
AU (1) AU2021218735A1 (https=)
IL (1) IL295427A (https=)
WO (1) WO2021163613A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026030341A1 (en) * 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
RU2692258C2 (ru) * 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
AU2019318888A1 (en) * 2018-08-07 2021-03-18 Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease

Also Published As

Publication number Publication date
CN115397849A (zh) 2022-11-25
US20230098944A1 (en) 2023-03-30
JP2026041805A (ja) 2026-03-10
WO2021163613A1 (en) 2021-08-19
JP2023513220A (ja) 2023-03-30
EP4103604A1 (en) 2022-12-21
IL295427A (en) 2022-10-01
AU2021218735A1 (en) 2022-09-01
EP4103604A4 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
KR20220142477A (ko) 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
JP4767982B2 (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
KR102188487B1 (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
KR102014875B1 (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
US20100099700A1 (en) Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
US20140288056A1 (en) Methods for non-toxic treatment for drug withdrawal
EP3813816B1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
US20190000863A1 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
CA3154744A1 (en) Glp-1 receptor agonists in dementia
JP2012500801A (ja) Ｃｎｓ疾患の治療法
WO2019205748A1 (zh) 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用
CN110300581A (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
HK40083593A (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
US12311005B2 (en) Pharmaceutical compositions and uses thereof in treating Parkinson's disease
EP3628315A1 (en) Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
EP2044944A1 (en) Nootropic medicinal agent
ES2357934B2 (es) Uso de un espirolido analogos y derivados para el tratamiento y/o la prevencion de patologias relacionadas con las proteinas tau y b-amiloide.
KR20250090047A (ko) 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물
CN120459095A (zh) 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途
WO2005082351A1 (ja) 神経変性疾患治療剤
CN120305240A (zh) 4-羟基扁桃酸类化合物用于制备预防或治疗阿尔茨海默病的药物的用途
CN117942336A (zh) Go6976在用于制备抗抑郁药物中的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902